Table 2– All factors investigated in primary univariate analysis
p-valueHazard ratio (95% CI)
Treatment duration0.6701.01 (0.95–1.08)
Age at treatment initiation0.3610.98 (0.94–1.02)
Female0.8750.94 (0.45–1.98)
Non-Caucasian0.090#2.03 (0.90–4.60)
Extrapulmonary involvement0.9641.03 (0.36–2.96
Biomarkers at start of therapy
 SUVmax
  Total0.033#1.10 (1.00–1.20)
  Lungs0.7031.02 (0.93–1.11)
  Mediastinum0.001#1.16 (1.06–1.26)
 ACE0.9251.00 (0.99–1.01)
 CRP0.7121.17 (0.52–2.63)
 sIL-2R0.103#1.00 (1.00–1.00)
 VC %0.4100.99 (0.97–1.01)
 FVC %0.3670.99 (0.97–1.01)
 FEV1 %0.6481.00 (0.98–1.02)
 Tiffeneau index0.9671.00 (0.97–1.03)
DLCO %0.2550.99 (0.96–1.01)
Biomarkers after 6 months of treatment
 SUVmax
  Total0.3121.12 (0.90–1.41)
  Lungs0.7581.08 (0.66–1.78)
  Mediastinum0.2261.14 (0.92–1.41)
 ACE0.8161.00 (0.99–1.02)
 CRP0.6371.25 (0.50–3.09)
 sIL-2R0.9571.00 (1.00–1.00)
 Leukocytes0.9410.99 (0.84–1.12)
Biomarkers at end of therapy
 ACE0.9171.00 (0.98–1.02)
 CRP0.3431.50 (0.65–3.43)
 sIL-2R0.8411.00 (1.00–1.00)
 Leukocytes0.7501.03 (0.86–1.24)
 VC %0.4060.99 (0.96–1.01)
 FEV1 %0.8391.00 (0.98–1.02)
 Tiffeneau index0.7621.01 (0.98–1.04)
DLCO %0.5420.99 (0.97–1.02)
Change in biomarkers
 ACE %0.6710.67 (0.99–1.00)
 sIL-2R %0.3741.00 (0.99–1.00)
 VC %0.8151.00 (0.95–1.04)
 FEV1 %0.6491.01 (0.97–1.05)
  • SUVmax: maximum standardised uptake value; ACE: angiotensin-converting enzyme; CRP: C-reactive protein; sIL-2R: soluble interleukin-2 receptor; VC: vital capacity; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusion capacity of the lung for carbon monoxide. #: all factors having p<0.2 were selected for further analysis in multivariate analysis.